Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASH18’

ASH is heading to San Diego!

Every year we eagerly await the American Society of Hematology (ASH) late breaking abstract reveal.  They can be sublime or disappointing, depending on the data available.

This year the conference is back in sunny San Diego.

We’ve already created some order from the chaos of the initial data dump and highlighted some key abstracts to watch out for in our first Preview post in the ASH18 series.

This time we look at what’s in store and – more importantly – what can we learn about the chosen LBA selections? What sort of caveats do we need to be mindful of?

It turns out that that’s quite a bit to think about…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Creating some semblance of order out of the ASH18 abstracts!

This is the first of our ASH 2018 preview series and looks beyond the obvious to many off-the-reservation type of abstracts, mostly within what can be classed as early new product development of Developmental Therapeutics.

In other words, what’s coming down the pike that looks intriguing, worrying or potentially useful?

There are likely to be a few obvious candidates, but also quite a few surprises in store for the unwary…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!